Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia

Frontiers in Pediatrics - Switzerland
doi 10.3389/fped.2015.00080
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2018English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Outcome of Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia After Blinatumomab Failure: No Change in the Level of CD19 Expression

American Journal of Hematology
Hematology
2017English

Immunotherapy for Pediatric Leukemia

Frontiers in Oncology
Cancer ResearchOncology
2013English

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Clinical Hematology International
2019English

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2017English

Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Identifying Leukemia-Specific Neoepitopes From Next-Generation Sequencing Data to Develop Targeted Immunotherapy for Pediatric Acute Myeloid Leukemiaig

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy